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Abstract 
 
Gene knockout approaches have helped to better understand the functions of the different Y receptors. 
However, some results obtained from these knockout mice are unexpected and differ from the results 
of pharmacological intervention experiments. One possible explanation for this is that germ-line gene 
deletion of a particular Y receptor can influence expression and function of the remaining Y receptors. 
Here we show that such compensation in mRNA and protein expression does occur in Y receptor 
single, double and triple knockout models.  Radio-ligand binding experiments using [125I]-PYY 
revealed significant up- and down-regulation of remaining Y receptor binding sites in various Y 
receptor knockout models compared to results from control mice employing Y receptor preferring 
agonist or antagonists for displacement of the radio-ligand. The most obvious change can be seen in the 
hippocampus of Y1 knockout mice, where the level of the remaining Y receptors is strongly down-
regulated. In Y2 knockout mice no such trend can be seen, however, the expression pattern is 
significantly changed with a strong up-regulation of [125I]-PYY specific binding in the dentate gyrus. 
Interestingly, this pattern was also seen in Y1Y2Y4 triple knockout mice. Y5 receptor mRNA was 
approximately 20% higher in the hippocampus and dentate gyrus in the triple knockout mice compared 
to wild-type controls, while Y6 mRNA expression could not be detected. However, competition 
binding experiments in Y1Y2Y4 triple knockout mice with the Y5 receptor preferring ligands [Leu
31, 
Pro34] NPY [A31, Aib32] and NPY were able to replace only approximately 50% of [125I]-PYY binding 
in the dentate gyrus suggesting the existence of further yet unidentified Y receptor(s).  	  
Abbreviations: Arc, arcuate hypothalamic nucleus; C1A, CA1 field of the hippocampus; C3A, CA3 
field of the hippocampus; DG, dentate gyrus; NTS, the nucleus of the solitary tract; NPY, neuropeptide 
Y; PVN, paraventricular nucleus; PYY, peptide YY; PP, pancreatic polypeptide  
1. Introduction  
The neuropeptide Y system consists of three peptide precursor genes encoding neuropeptide Y (NPY), 
peptide YY (PYY) and pancreatic polypeptide (PP) and at least 5 receptor genes encoding the Y1, Y2, 
Y4, Y5 and Y6 receptor (Tatemoto et al., 1982; Katayama-Kumoi et al., 1985; Dumont et al., 1992). 
NPY, which can act on all of these Y receptors, is a highly abundant neuropeptide and contributes to 
the regulation of a wide variety of important physiological functions (Lee et al., 2003; Parker et al., 
2000; Pedrazzini et al., 1998). The distribution of the different Y receptor types in mammalian brain, 
both by in situ analysis as well as by radio- ligand binding, has been well studied (Dumont et al., 1996; 
Martel et al., 1990; Parker and Herzog, 1999). In the rat, Y1 receptor specific binding is mainly found 
in the cerebral cortex, the dentate gyrus, as well as in thalamic and hypothalamic regions. The Y2 
receptor is found in a variety of areas, with highest binding levels in the hippocampus and brain stem 
(Dumont et al., 1990; Gehlert and Gackenheimer, 1997; Martel et al., 1990). Central Y4 receptor is 
primarily found in the nucleus of the solitary tract (NTS), the area postrema and also in the 
paraventricular nucleus (PVN) (Larsen and Kristensen, 2000; Parker and Herzog, 1999). Reasonable 
high Y5 receptor mRNA expression can be found in hypothalamic nuclei and in the hippocampus, 
however, Y5 receptor specific binding is surprisingly low (Dumont et al., 1998). Little is known about 
the expression of the Y6 receptor.  
  Studies describing the inactivation of Y1, Y2, Y4 and Y5 gene by homologous recombination have 
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been published. The analysis of the phenotypes of all these knockout models has revealed important 
functions of each gene in modulating feeding behavior, cardiovascular function, seizure susceptibility, 
pain perception, fertility and emotional behaviors (Herzog, 2003). However, some are unexpected 
findings and there is, in some cases, a lack of phenotype that would have been predicted from 
pharmacological approaches.  
  Removing one component of the NPY family system might lead to adaptive changes during 
development in order to maintain homeostasis. Due to their overlapping mRNA expression pattern and 
similar affinity for NPY, the remaining Y receptors could compensate when one of the others is 
missing. So far, only a few studies have addressed this question. Employing in situ hybridisation and 
receptor autoradiography using [125I]-PYY -(Leu31, Pro34)PYY and [125I]-PYY - (3–36) as radio-
ligands, the expression and binding of NPY receptors were investigated in the NPY-knockout mouse 
model (Trivedi et al., 2001). No significant change could be detected for Y1, Y4, Y5 and Y6 receptors. 
However, a 6-fold increase in Y2 receptor mRNA was observed in the CA1 region of the hippocampus. 
A 60–400% increase of Y2 receptor binding in a variety of brain areas confirmed this result. Y1 
receptor binding was also increased but only in the hypothalamus, confirming that the lack of the 
ligand gene can lead to alterations in Y receptor levels (Trivedi et al., 2001).  
  The aim of the present study was to systematically investigate whether the expression profile of 
different Y receptors is altered in the brain in response to single, double, or triple knockout of Y 
receptors. Several NPY analogues and Y receptor selective antagonists were used to determine the 
extent to which [125I]-PYY binding in the wild type brain was displaced compared to the levels found 
in the corresponding Y receptor knock-out mouse brains. Such understanding of the functional 
interactions among Y receptors and NPY in the compensation for lack of particular Y receptors could 
provide insight into the overlapping functions of various Y receptors.  
2. Materials and methods  
2.1. Animals  
Germ-line deletion of different Y receptor genes was achieved as previously described (Howell et al., 
2003; Sainsbury et al., 2003, 2002a,b,c). Animals were group-housed (2–3 animals per cage) and 
maintained under standard laboratory conditions with a 12:12 h light:dark schedule. At 16 weeks of 
age, ad libitum-fed male Y receptor knockout mice were killed by cervical dislocation at 11.00–14.00 h 
and the brain was removed and immediately frozen on dry ice until further use. All research and animal 
care procedures were approved by the ‘‘Garvan Institute/St. VincentÕs Hospital Animal 
Experimentation Ethics Committee’’ and were in agreement with the ‘‘Australian Code of Practice for 
the Care and Use of Animals for Scientific Purpose’’.  
2.2. In situ hybridisation and radio-ligand binding assays  
Coronal slices (20µm) were cut and thaw-mounted on charged slides. Matching brain sections from the 
same portion of hippocampus and Arc (approximately ︎1.94 mm from Bregma), PVN (-0.94 mm from 
Bregma) and NTS (-7.20 mm from Bregma) were collected. For in situ hybridisation, DNA 
oligonucleotides complementary to mouse NPY (5’-GAGGGTCAGTCCACACAGCCCCATTCGCT- 
TGTTACCTAGCAT-3’); mouse Y5 receptor-1 (5’-GGTGCACAGAGAGAATCATGACATGTGT- 
AGGCAGTGGATAAGGGC-3’); Y5 receptor-2 (TTTCTGGAACGGTTAGGTGCTTCTCCTGG- 
GAAGGTCCTGCTGGGG-3’); and mouse Y6 receptor-1 (5’-GCTCATTGGTGAGGTGGTAGGA- 
CAGGAATAAGGGAATAGACAATG-3’); Y6 receptor-2 (5’-CCAGGTCGTGGTGGCAGCTCAT- 
CAGCATCTCATGATACCAGTCGA-3’) mRNAs were labelled with [35S] thio-dATP (Amersham, 
Pharmacia or NEN) using terminal deoxynucleotidyltransferase (Roche, Mannheim, Germany or 
Amersham Pharmacia). Matching sections from the same portion of hippocampus of knockout and 
control mice were analysed together, as described previously (Sainsbury et al., 2002b). The mRNA 
levels were evaluated by measuring silver grain densities over individual neurons from photo-
emulsion-dipped sections, using National Institutes of Health image software (version number 1.63).  
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For receptor binding studies slides were thawed and pre-incubated for 30 min at room temperature in 
Krebs–Henseleit–Tris buffer (118 mM NaCl, 4.8 mM KCl, 1.3 mM MgSO4, 1.2 mM CaCl2, 50 mM 
glucose, 15 mM NaHCO3. 1.2 mM KH2PO4, 10 mM Tris, pH 7.3). Slides were then incubated with 
Krebs–Henseleit– Tris buffer supplemented with 0.1% bovine serum albu- min, 0.5% bacitracin and 25 
pM [125I]-PYY for 30 min at room temperature. Binding of pM [125I]-peptide YY binding was 
competed off by addition of 1 µM [Leu31, Pro34] NPY, [A31, Aib32] NPY, 1229U91, [(Leu31, Pro34) NPY 
(2–36), PP, or combinations of these ligands as described. Incubations with competing ligands were 
performed at room temperature for 2 h. Non-specific binding was determined in the presence of 1µM 
PYY. The sections were dipped twice and then washed for 30 s in ice-cold Krebs–Henseleit–Tris 
buffer, dipped in deionised water and rapidly dried under a stream of cold air. Finally the sections were 
developed by exposure to ßmax films (Kodak, Rochester, NY) for 7 days at -70ºC. The autoradiograms 
were developed and scanned, and identification of neural structures (Franklin and Paxinos, 1997) and 
relative optical density values were determined in regions of the hippocampus, DG, PVN, Arc and 
NTS. Specific binding was calculated by subtracting non-specific binding (obtained from sections 
incubated in 1000-fold excess cold PYY) from total binding. Non-specific labelling was uniform and 
never exceeded 5% of total signal in control.  
2.3. Statistical analysis  
  Differences among groups were assessed by factorial ANOVA, followed by Fisher’s post-hoc tests, 
using STAVIEW VERSION 4.5 (Abacus Concepts, Berkeley, CA). For all statistical analysis, P < 0.05 
was accepted as being statistically significant.  
3. Results  
3.1. Displacement of [125I]-peptide YY binding with Y receptor preferring ligands in wild type mice  
  In order to determine the contribution of the different Y receptors to total PYY binding, coronal brain 
sections at the level of the Arc, PVN and NTS from wild type mice were incubated with 25 pM [125I]-
PYY and displaced with either 1 µM the Y1 receptors antagonist 1229U91, the Y2 receptor antagonist 
BIIE0246 or the Y4 receptor agonist PP or in combinations of them as shown in Table 1. Unlabelled 
PYY at 1µM was used as control, resulting in complete displacement of [125I]-PYY (Table 1, Fig. 1). 
Addition of the Y1 antagonist 1229U91 caused an overall reduction of about 22% of [125I]-PYY 
binding in brain sections at -1.94 mm from Bregma. (Fig. 1, Table 1). Competition with the Y2 
antagonist BIIE0246 in consecutive sections replaced about 77% of the PYY binding (Fig. 1, Table 1). 
The Y4 agonist PP accounted for about 11% of [
125I]-PYY displacement (Fig. 1, Table 1). These data 
demonstrate that the highest contribution of [125I]-PYY binding in the sections of mouse brain at -1.94 
Bregma is attributed to the Y2 receptor. Combination treatment with the Y1, Y2 and Y4 receptor 
ligands caused further reductions in [125I]-PYY binding, leading to over 87% replacement of [125I]-
PYY binding in the triple ligand-treated group (Fig. 1, Table 1).  
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3.2. [125I]-peptide YY binding levels in different single and multiple Y receptor knockout mice  
  Coronal brain sections at the level of -1.94 mm from Bregma of Y receptor knockout mice were used 
in the analysis of [125I]-PYY binding. Compared to wild type mice, deletion of the Y1 receptor caused 
a reduction of 70% of total [125I]-PYY binding (Fig. 2, Table 2). This is significantly more compared 
to the 22% reduction seen in the wild type mice when using the Y1-specific antagonist 1229U91, 
suggesting a strong general down-regulation of Y receptor expression in the Y1 knockout mice. In 
comparison, the reduction in total binding in the Y2 knockout mice (76%) was similar to what was 
seen in the displacement with the Y2 antagonist BIIE0246 in wild type mice (Fig. 2, Tables 1 and 2). 
However, a clear difference in the expression pattern can be seen between these two Y2 ablation 
models, with the Y2 antagonist treated brains showing the strongest remaining binding in the strata 
radiatum and oriens in areas CA1 to CA3 of the hippocampus (Fig. 1(c)). Y2 knockout mouse brains 
on the other hand show the den- tate gyrus as the major structure containing remaining [125I]-PYY 
binding (Fig. 2(c)), suggesting significant compensatory changes in the hippocampus of Y2 recep- tor 
knockout mice. The change in total [125I]-PYY binding in Y4 knockout mice (8%) is similar to what 
was seen in the displacement experiment using the Y4-specific agonist PP (Fig. 2, Tables 1 and 2). 
There are no obvious differences between the patterns of expression of non-Y4 binding in these two 
models (Fig. 1(d) vs. 2(d)).  
  Double knockout of the Y1 and Y2 receptor as well as Y2 and Y4 receptor resulted in slightly further 
reductions in binding compared to the single Y2 receptor knockouts. As in the single Y2 knockout, the 
remaining binding in Y1Y2 and Y2Y4 double knockouts was present in the dentate gyrus. Triple 
knockout of the Y1, Y2 and Y4 receptor further reduced the level of [
125I]-PYY binding, with about 
14% remaining (Table 2, Fig. 2(g)). This level of remaining binding is very similar to the 13% seen in 
the displacement experiment (Table 1), however, the altered expression pattern in the hippocampus 
between the ligand displacement study vs. knockout mouse study already seen in the Y2 knockout mice 
is also present (Fig. 1(g) vs. 2(g)).  
3.3. [125I]-peptide YY binding levels in different nuclei of the hypothalamus, hippocampus and brain 
stem of Y receptor knockout mice  
  Specific analysis of the Arc, the PVN, the hippocampus, the dentate gyrus and the NTS of knockout 
mice revealed that the greatest reduction in [125I]-PYY binding is observed in the Y2 knockout mouse, 
at room temperature. Binding of [125I]-peptide YY bind-
ing was competed oﬀ by addition of 1 lM [Leu31, Pro34]
NPY, [A31, Aib32] NPY, 1229U91, [Leu31, Pro34] NPY
(2–36), PP, or combinations of these ligands as de-
scribed. Incubations with competing ligands were per-
formed at room temperature for 2 h. Non-specific
binding was determined in the presence of 1 lM PYY.
The sections were dipped twice and then washed for
30 s in ice-cold Krebs–Henseleit–Tris buﬀer, dipped in
deionised water and rapidly dried under a stream of cold
air. Finally the sections were developed by exposure to
ßmax films (Kodak, Rochester, NY) for 7 days at
!70oC. The autoradiograms were developed and
scanned, and identification of neural structures (Frank-
lin and Paxinos, 1997) and relative optical density values
were determined in regions of the hippocampus, DG,
PVN, Arc and NTS. Specific binding was calculated
by subtracting non-specific binding (obtained from s c-
tions incubated in 1000-fold excess cold PYY) from to-
tal binding. Non-specific labelling was uniform and
never exceeded 5% of total signal in control.
2.3. Statistical analysis
Diﬀerences among groups were assessed by factorial
ANOVA, followed by Fisher!s post-hoc tests, using
STAVIEW VERSION 4.5 (Abacus Concepts, Berkeley,
CA). For all statistical analysis, P < 0.05 was accepted
as being statistically significant.
3. Results
3.1. Displacement of [125I]-peptide YY binding with Y
receptor preferring ligands in wild type mice
In order to determine the contribution of the diﬀerent
Y receptors to total PYY binding, coronal brain sections
at the level of the Arc, PVN and NTS from wild type
mice were incubated with 25 pM [125I]-PYY and dis-
placed with either 1 lM the Y1 receptors antagonist
1229U91, the Y2 receptor antagonist BIIE0246 or the
Y4 receptor agonist PP or in combinations of them as
shown in Table 1. Unlabelled PYY at 1 lM was used
as control, resulting in complete displacement f [125I]-
PYY (Table 1, Fig. 1). Addition of the Y1 antagonist
1229U91 caused an overall reduction of about 22% of
[125I]-PYY binding in brain sections at !1.94 mm from
Bregma. (Fig. 1, Table 1). Competition with the Y2
antagonist BIIE0246 in consecutive sections replaced
about 77% of the PYY binding (Fig. 1, Table 1). The
Y4 agonist PP accounted for about 11% of [
125I]-PYY
displacement (Fig. 1, Table 1). These data demonstrate
that the highest contribution of [125I]-PYY binding in
the sections of mouse brain at !1.94 Bregma is attrib-
uted to the Y2 receptor. Combination treatment with
the Y1, Y2 and Y4 receptor ligands caused further reduc-
tions in [125I]-PYY binding, leading to over 87% replace-
ment of [125I]-PYY binding in the triple ligand-treated
group (Fig. 1, Table 1).
3.2. [125I]-peptide YY binding leve s in diﬀerent single
and multiple Y rec ptor knocko t mice
Coronal brain sections at the level of !1.94 mm from
Bregma of Y receptor knockout mice were used in the
Table 1
Displacement of [125I]-PYY binding to the brain of wild type mice by
diﬀerent Y receptor ligands
Y receptor ligands Binding levels (%)
[125I]-PYY 100 ± 3.0 (5)
1229U91 77.8 ± 2.4(5)
BIIE0246 22.4 ± 1.0 (5)
PP 88.7 ± 2.3 (5)
1229U91 + BIIE0246 15.2 ± 1.4 (4)
PP + BIIE0246 19.8 ± 2.1 (5)
1229U91 + PP + BIIE0246 12.9 ± 1.2 (5)
Data represent mean [125I]-PYY binding levels in the brain sections of
wild type mice after displacement with diﬀerent Y receptor ligands,
given as percent of total [125I]-PYY binding ± SE. The number of mice
is shown in parentheses. 1229U91, selective Y1 antagonist; BIIE0246,
selective Y2 antagonist; PP, pancreatic polypeptide, selective Y4
agonist.
Fig. 1. Film autoradiographs show the eﬀect of diﬀerent Y receptor
ligands on [125I]-peptide YY binding levels in the brain section of wild
type mice. The [125I]-peptide YY binding levels are presented as a
percentage (see Table 1) compared to those in the control (WT, wild
type mice). Data are means for six mice per group. U91, 1229U91;
BIIE, BIIE0246; PP, pancreatic polypeptide. Control, unspecific
binding determined i the presence of 1 lM NPY.
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except in the dentate gyrus (Fig. 3). Y1 receptor deletion also significantly reduced [
125I]-PYY binding 
in all areas investigated including the dentate gyrus. Single Y4 receptor knock- out only caused a 
significant reduction in [125I]-PYY binding in the PVN and NTS, consistent with the known 
expression of the mRNA for the Y4 receptor (Parker and Herzog, 1999). Double and triple knockout of 
the different Y receptors had little additional effect on the al- ready strongly reduced [125I]-PYY 
binding levels seen in the Y2 knockout mice.  
 
at room temperature. Binding of [125I]-peptide YY bind-
ing was competed oﬀ by addition of 1 lM [Leu31, Pro34]
NPY, [A31, Aib32] NPY, 1229U91, [Leu31, Pro34] NPY
(2–36), PP, or combinations of these ligands as de-
scribed. Incubations with competing ligands were per-
formed at room temperature for 2 h. Non-specific
binding was determined in the presence of 1 lM PYY.
The sections were dipped twice and then washed for
30 s in ice-cold Krebs–Henseleit–Tris buﬀer, dipped in
deionised water and rapidly dried under a stream of cold
air. Finally the sections were developed by exposure to
ßmax films (Kodak, Rochester, NY) for 7 days at
!70oC. The autoradiograms were developed and
scanned, and identification of neural structures (Frank-
lin and Paxinos, 1997) and relative optical density values
were determined in regions of the hippocampus, DG,
PVN, Arc and NTS. Specific binding was calculated
by subtracting non-specific binding (obtained from sec-
tions incubated in 1000-fold excess cold PYY) from to-
tal binding. Non-specific labelling was uniform and
never exceeded 5% of total signal in control.
2.3. Statistical analysis
Diﬀerences among groups were assessed by factorial
ANOVA, followed by Fisher!s post-hoc tests, using
STAVIEW VERSION 4.5 (Abacus Concepts, Berkeley,
CA). For all statistical analysis, P < 0.05 was accepted
as being statistically significant.
3. Results
3.1. Displacement of [125I]-peptide YY binding with Y
receptor preferring ligands in wild type mice
In order to determine the contribution of the diﬀerent
Y receptors to total PYY binding, coronal brain sections
at the level of the Arc, PVN and NTS from wild type
mice were incubated with 25 pM [125I]-PYY and dis-
placed with either 1 lM the Y1 receptors antagonist
1229U91, the Y2 receptor antagonist BIIE0246 or the
Y4 receptor agonist PP or in combinations of them as
shown in Table 1. Unlabelled PYY at 1 lM was used
as control, resulting in complete displacement of [125I]-
PYY (Table 1, Fig. 1). Addition of the Y1 antagonist
1229U91 caused an overall reduction of about 22% of
[125I]-PYY binding in brain sections at !1.94 mm from
Bregma. (Fig. 1, Table 1). Competition with the Y2
antagonist BIIE0246 in consecutive sections replaced
about 77% of the PYY binding (Fig. 1, Table 1). The
Y4 agonist PP accounted for about 11% of [
125I]-PYY
displacement (Fig. 1, Table 1). These data demonstrate
that the highest contribution of [125I]-PYY binding in
the sections of mouse brain at !1.94 Bregma is attrib-
uted to the Y2 receptor. Combination treatment with
the Y1, Y2 and Y4 receptor ligands caused further reduc-
tions in [125I]-PYY binding, leading to over 87% replace-
ment of [125I]-PYY binding in the triple ligand-treated
group (Fig. 1, Table 1).
3.2. [125I]-peptide YY binding levels in diﬀerent single
and multiple Y receptor knockout mice
Coronal brain sections at the level of !1.94 mm from
Bregma of Y receptor knockout mice were used in the
Table 1
Displacement of [125I]-PYY binding to the brain of wild type mice by
diﬀerent Y receptor ligands
Y receptor ligands Binding levels (%)
[125I]-PYY 100 ± 3.0 (5)
1229U91 77.8 ± 2.4(5)
BIIE0246 22.4 ± 1.0 (5)
PP 88.7 ± 2.3 (5)
1229U91 + BIIE0246 15.2 ± 1.4 (4)
PP + BIIE0246 19.8 ± 2.1 (5)
1229U91 + PP + BIIE0246 12.9 ± 1.2 (5)
Data represent mean [125I]-PYY binding levels in the brain sections of
wild type mice after displacement with diﬀerent Y receptor ligands,
given as percent of total [125I]-PYY binding ± SE. The number of mice
is shown in parentheses. 1229U91, selective Y1 antagonist; BIIE0246,
selective Y2 antagonist; PP, pancreatic polypeptide, selective Y4
agonist.
Fig. 1. Film autoradiographs show the eﬀect of diﬀerent Y receptor
ligands on [125I]-peptide YY binding levels in the brain section of wild
type mice. The [125I]-peptide YY binding levels are presented as a
percentage (see Table 1) compared to those in the control (WT, wild
type mice). Data are means for six mice per group. U91, 1229U91;
BIIE, BIIE0246; PP, pancreatic polypeptide. Control, unspecific
binding determined in the presence of 1 lM NPY.
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analysis of [125I]-PYY binding. Compared to wild type
mice, deletion of the Y1 receptor caused a reduction of
70% of total [125I]-PYY binding (Fig. 2, Table 2). This
is significantly more compared to the 22% reduction
seen in the wild type mice when using the Y1-specific
antagonist 1229U91, suggesting a strong general
down-regulation of Y receptor expression in the Y1
knockout mice. In comparison, the reduction in total
binding in the Y2 knockout mice (76%) was similar to
what was seen in the displacement with the Y2 antago-
nist BIIE0246 in wild type mice (Fig. 2, Tables 1 and
2). However, a clear diﬀerence in the expression pattern
can be seen between these two Y2 ablation models, with
the Y2 antagonist treated brains showing the strongest
remaining binding in the strata radiatum and oriens in
areas CA1 to CA3 of the hippocampus (Fig. 1(c)). Y2
knockout mouse brains on the other hand show the den-
tate gyrus as the major structure containing remaining
[125I]-PYY binding (Fig. 2(c)), suggesting significant
compensatory changes in the hippocampus of Y2 recep-
tor knockout mice. The change in total [125I]-PYY bind-
ing in Y4 knockout mice (8%) is similar to what was seen
in the displacement experiment using the Y4-specific
agonist PP (Fig. 2, Tables 1 and 2). There are no obvi-
ous diﬀerences between the patterns of expression of
non-Y4 binding in these two models (Fig. 1(d) vs. 2(d)).
Double knockout of the Y1 and Y2 receptor as well as
Y2 and Y4 receptor resulted in slightly further reduc-
tions in binding compared to the single Y2 receptor
knockouts. As in the single Y2 knockout, the remaining
binding in Y1Y2 and Y2Y4 double knockouts was pres-
ent in the dentate gyrus. Triple knockout of the Y1, Y2
and Y4 receptor further reduced the level of [
125I]-PYY
binding, with about 14% remaining (Table 2, Fig.
2(g)). This level of remaining binding is very similar to
the 13% seen in the displacement experiment (Table 1),
however, the altered expression pattern in the hippo-
campus between the ligand displacement study vs.
knockout mouse study already seen in the Y2 knockout
mice is also present (Fig. 1(g) vs. 2(g)).
3.3. [125I]-peptide YY binding levels in diﬀerent nuclei of
the hypothalamus, hippocampus and brain stem of Y
receptor knockout mice
Specific analysis of the Arc, the PVN, the hippocam-
pus, the dentate gyrus and the NTS of knockout mice re-
vealed that the greatest reduction in [125I]-PYY binding
is observed in the Y2 knockout mouse, except in the den-
tate gyrus (Fig. 3). Y1 receptor deletion also significantly
reduced [125I]-PYY binding in all areas investigated
including the dentate gyrus. Single Y4 receptor knock-
out only caused a significant reduction in [125I]-PYY
binding in the PVN and NTS, consistent with the known
expression of the mRNA for the Y4 receptor (Parker
and Herzog, 1999). Double and triple knockout of the
diﬀerent Y receptors had little additional eﬀect on the al-
ready strongly reduced [125I]-PYY binding levels seen in
the Y2 knockout mice.
To further characterise the nature of the remaining
[125I]-PYY binding sites in the Y1Y2Y4 receptor triple
knockout mice we performed [125I]-PYY displacement
experiments on the brains from these mice using the
NPY peptide analogous [Leu31, Pro34] NPY, NPY (2–
36) and [A31, Aib32] NPY, all known to have Y5 receptor
preference (Dumont et al., 2003; Grundemar, 1998).
Although all peptides were able to reduce [125I]-PYY
binding in the dentate gyrus of triple knockout mice
by 18%, 46% and 37%, respectively, none of them were
Fig. 2. Film autoradiographs show [125I]-peptide YY binding on the
brain sections of diﬀerent Y receptor knockout mice. The [125I]-peptide
YY binding levels are expressed as a percentage (see Table 2)
compared to those in wild type mice. Data are means for six mice
per group. Control, unspecific binding determined in the presence of 1
lM NPY.
Table 2
[125I]-PYY binding levels in the brain sections of wild type and diﬀerent
groups of Y knockout mice
Animals Binding levels (%)
Wild type 100 ± 2.8 (5)
Y
!=!
1 30.2 ± 2.7 (5)
Y
!=!
2 23.1 ± 1.8 (5)
Y
!=!
4 92.1 ± 2.6 (5)
Y
!=!
1 Y
!=!
2 17.7 ± 0.9 (5)
Y
!=!
2 Y
!=!
4 21.7 ± 2.5 (5)
Y
!=!
1 Y
!=!
2 Y
!=!
4 14.1 ± 0.8 (5)
Data represent mean [125I]-PYY binding levels in the brain sections of
wild type and diﬀerent groups of Y knockout mice, given as percent of
wild type ± SE. The number of mice is shown in parentheses.
Y
!=!
1 ;Y
!=!
2 ;Y
!=!
4 ;Y
!=!
1 Y
!=!
2 ;Y
!=!
2 Y
!=!
4 and Y
!=!
1 Y
!=!
2 Y
!=!
4 are rep-
resented as diﬀerent Y knockout mice.
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  To further characterise the nature of the remaining [125I]-PYY binding sites in the Y1 Y2 Y4 receptor 
triple 124 knockout mice we performed [125I]-PYY displacement experiments on the brains from these 
mice using the NPY peptide analogous [Leu31, Pro34] NPY, NPY (2– 36) and [A31, Aib32] NPY, all 
known to have Y5 receptor preference (Dumont et al., 2003; Grundemar, 1998). Although all peptides 
were able to reduce [125I]-PYY binding in the dentate gyrus of triple knockout mice by 18%, 46% and 
37%, respectively, none of them were able to compete off all of the radio-labelled [125I]-PYY (Fig. 4). 
A 20% up-regulation of Y5 receptor mRNA levels in the hippocampus and dentate gyrus of Y1Y2Y4 
triple knockout mice compared to wild type mice was confirmed by in situ hybridisation (data not 
shown).  
  As no selective Y6 receptor ligands are known we investigated the possibility that the Y6 receptor 
could account for the remaining [125I]-PYY binding in Y1Y2Y4 triple knockout mice by in situ 
hybridisation. Using a mouse Y6 receptor specific probe we were unable to de- tect any expression of 
this receptor in the brain regions shown in Figs. 1 and 2 at Bregma ︎-1.94 mm (data not shown), 
suggesting the existence of further unknown Y receptor(s) other than the Y6 receptor.  
 
4. Discussion  
This study shows for the first time that germ-line deletion of Y receptors results in changes in not only 
the expression levels, but also of the distribution pattern of other Y receptors within the brain. These 
changes in brain Y receptor expression profiles may contribute to some of the phenotypes observed in 
various Y receptor knockout mice. It may also explain some of the discrepancies between observations 
in Y receptor knockout mice and the phenotypes that would have been expected from pharmacological 
intervention studies in wild type animals.  
  Our binding study, using the Y1-specific antagonist 1229U91 to displace [
125I]-PYY binding, 
suggested that Y1 receptors only contribute to 22% of the [
125I]-PYY binding sites in the brain. In 
contrast, germ-line deletion of Y1 receptors caused a 70% decrease in total brain [
125I]-PYY binding. 
Similar, large reductions in [125I]-PYY binding were observed in specific regions such as the Arc, 
PVN and dentate gyrus of Y1 receptor knock- out mice. This discrepancy suggests that Y1 deficiency 
during development leads to the down regulation of other Y receptors in these brain regions. The Y 
receptor down-regulated by germ-line Y1 deficiency is most likely to be the Y2 receptor, because this 
Y receptor accounts for most of the PYY binding in wild type mice. Pharma- cological studies have 
implicated Y1 receptors in mediat- ing the feeding stimulatory effect of NPY. However, Y1 knockout 
mice exhibit only a slight (Pedrazzini et al., 1998) or non-significant (Kushi et al., 1998) reduction in  
analysis of [125I]-PYY bi ding. Compa ed to wild type
mice, deletion of the Y1 receptor caused a reduction of
70% of total [125I]-PYY binding (Fig. 2, Table 2). This
is significantly more compared to the 22% reduction
seen in the wild type mice when using the Y1-specific
antagonist 1229U91, suggesting a strong general
down-regulation of Y receptor expression in the Y1
knockout mice. In comparison, the reduction in total
bind g in the Y2 knockout mice (76%) was similar o
what was seen in the displacement with the Y2 antago-
nist BIIE0246 in wild type mice (Fig. 2, Tables 1 and
2). However, a clear diﬀerence in the expression pattern
can be seen between these two Y2 ablation models, with
the Y2 antagonist treated brains showing the strongest
remaining binding in the strata radiatum and oriens in
areas CA1 to CA3 of the hippocampus (Fig. 1(c)). Y2
knockout mouse brains on the other hand show the den-
tate gyrus as the major structure containing remaining
[125I]-PYY binding (Fig. 2(c)), suggesting significant
compensatory changes in the hippocampus of Y2 recep-
tor knockout mice. The change in total [125I]-PYY bind-
ing in Y4 knockout mice (8%) is similar to what was seen
in the displacement experiment using the Y4-specific
agonist PP (Fig. 2, Tables 1 and 2). There are no obvi-
ous diﬀerences between the patterns of expression of
non-Y4 binding in these two models (Fig. 1(d) vs. 2(d)).
Double knockout of the Y1 and Y2 receptor as well as
Y2 and Y4 receptor resulted in slightly further reduc-
tions in binding compared to the single Y2 receptor
knockouts. As in the single Y2 knockout, the remaining
binding in Y1Y2 and Y2Y4 double knockouts was pres-
ent in the dentate gyrus. Triple knockout of the Y1, Y2
and Y4 receptor further reduced the level of [
125I]-PYY
binding, with about 14% remaining (Table 2, Fig.
2(g)). This level of remaining binding is very similar to
the 13% seen in the displacement experiment (Table 1),
however, the altered expression pattern in the hippo-
campus between the ligand displacement study vs.
knockout mouse study already seen in the Y2 knockout
mice is also present (Fig. 1(g) vs. 2(g)).
3.3. [125I]-peptide YY binding levels in diﬀerent nuclei of
the hypothalamus, hippocampus and brain stem of Y
receptor knockout mice
Specific analysis of the Arc, the PVN, the hippocam-
pus, the dentate gyrus and the NTS of knockout mice re-
veal d that the greatest reduction in [125I]-PYY binding
is observed in the Y2 knockout mouse, except in the den-
tate gyrus (Fig. 3). Y1 receptor deletion also significantly
reduced [125I]-PYY binding in all areas investigated
including the dentate gyrus. Single Y4 receptor knock-
out only caused a significant reduction in [125I]-PYY
binding in the PVN and NTS, consistent with the known
expression of the mRNA for the Y4 receptor (Parker
and Herzog, 1999). Double and triple knockout of the
diﬀerent Y receptors had little additional eﬀect on the al-
ready strongly reduced [125I]-PYY binding levels seen in
the Y2 knockout mice.
To further characterise the nature of the remaining
[125I]-PYY binding sites in the Y1Y2Y4 receptor triple
knockout mice we performed [125I]-PYY displacement
experiments on the brains from these mice using the
NPY peptide analogous [Leu31, Pro34] NPY, NPY (2–
36) and [A31, Aib32] NPY, all known to have Y5 receptor
preference (Dumont et al., 2003; Grundemar, 1998).
Although all peptides were able to reduce [125I]-PYY
binding in the dentate gyrus of triple knockout mice
by 18%, 46% and 37%, respectively, none of them were
Fig. 2. Film autoradiographs show [125I]-peptide YY binding on the
brain sections of diﬀerent Y receptor knockout mice. The [125I]-peptide
YY binding levels are expressed as a percentage (see Table 2)
compared to those in wild type mice. Data are means for six mice
per group. Control, unspecific binding determined in the presence of 1
lM NPY.
Table 2
[125I]-PYY binding levels in the brain sections of wild type and diﬀerent
groups of Y knockout mice
Animals Binding levels (%)
Wild type 100 ± 2.8 (5)
Y
!=!
1 30.2 ± 2.7 (5)
Y
!=!
2 23.1 ± 1.8 (5)
Y
!=!
4 92.1 ± 2.6 (5)
Y
!=!
1 Y
!=!
2 17.7 ± 0.9 (5)
Y
!=!
2 Y
!=!
4 21.7 ± 2.5 (5)
Y
!=!
1 Y
!=!
2 Y
!=!
4 14.1 ± 0.8 (5)
Data represent mean [125I]-PYY binding levels in the brain sections of
wild type and diﬀerent groups of Y knockout mice, given as percent of
wild type ± SE. The number of mice is shown in parentheses.
Y
!=!
1 ;Y
!=!
2 ;Y
!=!
4 ;Y
!=!
1 Y
!=!
2 ;Y
!=!
2 Y
!=!
4 and Y
!=!
1 Y
!=!
2 Y
!=!
4 are rep-
resented as diﬀerent Y knockout mice.
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spontaneous daily food intake, with no significant de- crease in NPY-induced feeding, albeit they do 
exhibit significant reductions in fasting-induced re-feeding (Pedrazzini et al., 1998). It was considered 
that up-regulation of other Y receptors, such as Y5 receptors, which have also been implicated in NPY-
induced feeding (Marsh et al., 1998), would account for the lack of obvious hypophagia in Y1 
knockouts. Our current data show however that this is not the case. By contrast, it is possible that 
down-regulation of the Y2 receptor, which has been shown to play an important role in mediating 
satiety (Batterham et al., 2002; Leibowitz and Alexander, 1991; Pierroz et al., 1996; Sainsbury et al., 
2002a) could explain, at least in part, the lack of obvious hypophagic phenotype in the Y1 knockout 
mice.  
  Germ-line deletion of the Y2 or the Y4 receptor does not seem to influence the overall expression 
level of other Y receptors, since the reduction in [125I]-PYY specific binding in the knockout animals 
is similar to that predicted from the pharmacological displacement studies using Y2- and Y4-specific 
ligands in wild type mice. However, germ-line Y2 receptor deletion causes a significant change in 
expression pattern of the remaining Y receptors, particular in the hippocampus, where a strong increase 
in [125I]-PYY specific binding can be detected in the dentate gyrus in Y2 deficient mice. Interestingly 
this change is not due to up-regulation of Y1 or Y4 receptors in this area, since the effect persists in 
double and triple knockout mice. Some of this increase in [125I]-PYY binding in the dentate gyrus can 
be attributed to the Y5 receptor, as expression of Y5 mRNA is increased by about 20% in this area in 
Y1Y2Y4 receptor deficient mice. However, competition binding experiments on the brains of Y1Y2Y4 
triple knockout mice employing Y5 preferring ligands show that Y5 binding sites only ac- count for 
approximately 50% of the [125I]-PYY binding in the dentate gyrus of the triple knockouts. No selective 
able to compete oﬀ all f the radio-labelled [125I]-PYY
(Fig. 4). A 20% up-regulation of Y5 receptor mRNA lev-
els in the hippocampus and dentate gyrus of Y1Y2Y4 tri-
ple knockout mice compared to wild type mice was
confirmed by in situ hybridisation (data not shown).
As no selective Y6 receptor ligands are known we
investigated the p ssibility that th Y6 eceptor could ac-
count for the remaining [125I]-PYY binding in Y1Y2Y4
triple knockout mice by in situ hybridisation. Using a
mouse Y6 receptor specific probe we were unable to de-
tect any expression of this receptor in the brain regions
shown in Figs. 1 and 2 at Bregma !1.94 mm (data not
shown), suggesting the existence of further unknown Y
receptor(s) other than the Y6 receptor.
4. Discus io
This study shows for the first time that germ-line
deletion of Y receptors results in changes in not only
the expression levels, b t also of the distribution pattern
of other Y receptors within the brain. These changes in
brain Y receptor expression profiles may contribute to
some of the phenotypes observed in various Y receptor
knockout mice. It may also explain some of the discrep-
ancies between observations in Y receptor knockout
mice and the phenotypes that would have been expected
from pharmacological intervention studies in wild type
animal .
Our binding study, using the Y1-specific antagonist
1229U91 to displace [125I]-PYY binding, suggested that
Y1 receptors only contribute to 22% of the [
125I]-PYY
binding sites in the brain. In contrast, germ-line deletion
of Y1 receptors caused a 70% decrease in total brain
[125I]-PYY binding. Similar, large reductions in [125I]-
PYY binding were observed in specific regions such as
the Arc, PVN and dentate gyrus of Y1 receptor knock-
out mice. This discrepancy suggests that Y1 deficiency
during development leads to the down regulation of
oth r Y receptor in these brain regions. The Y receptor
down-regulated by germ-line Y1 deficiency is most likely
to be the Y2 receptor, because this Y receptor accounts
for most of the PYY binding in wild type mice. Pharma-
cological tudies hav implicated Y1 receptors in mediat-
ing the feeding stimulatory eﬀect of NPY. However, Y1
knockout mice exhibit only a slight (Pedrazzini et al.,
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Fig. 3. [125I]-peptide YY binding levels in the brain of diﬀerent Y receptor knockout mice are expressed as a percentage compared to those in wild
type controls. [125I]-peptide YY binding levels are showed in: (a) the arcuate hypothalamic nucleus (Arc), (b) the paraventricular nucleus (PVN), (c)
the hippocampus, (d) the dentate gyrus (DG) and (e) the nucleus of solitary tract (NTS). Data are means ± SE of the means for six mice per group. *,
P < 0.05 vs. control mice. WT, wild type control; Y1, Y2, Y4, Y1,2, Y2,4 and Y1,2,4 are represented as diﬀerent Y knockout mouse models.
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ligands are known for the only other described Y receptor, the Y6 receptor. However, the Y6 receptor 
can be excluded as a candidate for these remaining [125I]-PYY binding sites in the dentate gyrus of 
triple knockout mice, as no Y6 mRNA expression can be detected in this area. These findings, in 
addition to the fact that these experiments were performed with a concentration of radio-labelled ligand 
[125I]-PYY that does not produce any background binding, because it can be completely competed off 
with non-radio-labelled PYY, suggest the possibility of the existence of a further, so far unknown Y 
receptor(s).  
  Pharmacological studies have described such potential additional Y receptors, notably the NPY-
preferring Y3 receptor (Glaum et al., 1997; Lee and Miller, 1998). Radio-ligand binding studies using 
labelled PP also speculate about additional, as yet unidentified Y receptors (Dumont et al., 2004). 
However, as no molecular cloning of any of these potential Y receptors has been reported, controversy 
still surrounds their existence (Goumain et al., 2001; Herzog et al., 1993). It is unlikely that the [125I]-
PYY binding detected in the triple knock- out mice can be attributed to a Y3 receptor, since as per 
definition the Y3 receptor only binds NPY and not PYY (Dumont et al., 1993; Jacques et al., 1995). 
Early reports have also suggested that NPY and PYY can interact with sigma receptors in the mouse 
hippocampus (Bouchard et al., 1993), a possibility that could be considered, as could the possibility of 
a novel unknown Y receptor. Unfortunately, even with the completion of sequencing of several 
genomes, the identification of additional Y receptors is difficult due to the low sequence homology 
between members of the Y receptor family. However, as many orphan G-protein coupled receptors still 
await the identification of their natural ligand, there is potential that one or more of such orphan 
receptors can recognise members of the NPY family.  
  In summary, our results show that the deletion of different Y receptors leads to varied reduction in the 
binding affinity of [125I]-PYY in specific brain regions of knockout mice. Contrary to current dogma, 
our data shows that deletion of Y receptors did not lead to over- all up-regulation of other Y receptor 
binding sites and in fact Y1 deletion actually led to down-regulation of total Y receptor binding. It is 
likely that these changes in Y receptor binding and distribution could contribute to at least part of the 
phenotypes observed in various Y receptor knockout mouse models. Our findings also provide strong 
evidence for the existence of further Y receptors.  
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